Lucid Diagnostics Exceeds Test Targets With 3,177 Tests, Raises $16.8M
LUCD•Lucid Diagnostics performed 3,177 e-cigarette tests in Q1, surpassing its 2,500–3,000 target, and raised $16.8 million in a public offering to bring pro forma cash to $45 million. Q1 revenue dipped to $1.3 million as Medicare coverage delays affecting 40–50% of patients and reimbursement transitions introduced volatility.
1. Q1 Test Volume and Revenue
Lucid Diagnostics completed 3,177 e-cigarette tests in Q1, exceeding its target range of 2,500 to 3,000 tests. Despite this operational milestone, revenue for the quarter was $1.3 million, down slightly due to a decrease in test volume compared to prior period metrics.
2. Cash Position and Financing
The company raised approximately $16.8 million through a public offering, boosting its pro forma cash position to $45 million. This enhanced liquidity is intended to support commercialization efforts, laboratory expansions, and ongoing research initiatives in 2026.
3. Reimbursement and Contracts
Lucid secured a federal supply schedule contract with the Department of Veterans Affairs, enabling direct engagement with individual VA centers. However, delays in Medicare coverage decisions affecting 40–50% of the addressable patient base, along with transitional reimbursement processes and local coverage determination backlogs, are creating revenue recognition volatility. The company is also pursuing additional policies with commercial payers and laboratory benefit managers to expand coverage.
